An investigational study to learn whether regular healthcare, combined with early treatment with a cholesterol lowering drug called evolocumab (Repatha®) reduces heart attack, stroke, procedures to improve blood flow, and death, compared to regular healthcare alone.
Contact phone
Sparrow Clinical Research Institute | 517.364.5760
Contact email
Principal investigator
Dr. Chad Link, DO, FACC
Trial Category
Heart & Vascular
Trial SubCategory
Lipid Management